Several of currently used drugs are chiral compounds. Majority of them are clinically administered as a racemic (equimolar) mixture of enantiomers. Individual enantiomers of one drug can qualitatively and quantitatively differ in their biological activities (pharmacology, toxicology, pharmacokinetics, etc.). Therefore, enantiopure drugs have been developed and introduced to the therapy. Statins are drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase. Atorvastatin, rosuvastatin and fluvastatin are the most often prescribed statins. They have two chiral centres, thus they form four enantiomers: 3R5R-, 3R5S-, 3S5R-and 3S5S- (Figure 1 ). They are marketed as a racemic mixture of these enantiomers; however their enantiopure forms have been introduced to clinic recently (3R5R-atorvastatin, 3R5S-rosuvastatin and 3R5S-fluvastatin). In this study, we investigated enantiospecific interactions of all four enantiopure forms of atorvastin, rosuvastatin and fluvastatin with main transcriptional regulators of drugmetabolizing enzymes -aryl hydrocarbon receptor (AhR), glucocorticoid receptor (GR) and pregnane X receptor (PXR). Agonist and antagonist activities of tested compounds towards AhR, PXR and GR were determined using human reporter cell lines.
Introduction:
Several of currently used drugs are chiral compounds. Majority of them are clinically administered as a racemic (equimolar) mixture of enantiomers. Individual enantiomers of one drug can qualitatively and quantitatively differ in their biological activities (pharmacology, toxicology, pharmacokinetics, etc.) . Therefore, enantiopure drugs have been developed and introduced to the therapy. Statins are drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase. Atorvastatin, rosuvastatin and fluvastatin are the most often prescribed statins. They have two chiral centres, thus they form four enantiomers: 3R5R-, 3R5S-, 3S5R-and 3S5S- (Figure 1 ). They are marketed as a racemic mixture of these enantiomers; however their enantiopure forms have been introduced to clinic recently (3R5R-atorvastatin, 3R5S-rosuvastatin and 3R5S-fluvastatin). In this study, we investigated enantiospecific interactions of all four enantiopure forms of atorvastin, rosuvastatin and fluvastatin with main transcriptional regulators of drugmetabolizing enzymes -aryl hydrocarbon receptor (AhR), glucocorticoid receptor (GR) and pregnane X receptor (PXR). Agonist and antagonist activities of tested compounds towards AhR, PXR and GR were determined using human reporter cell lines.
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Gene reporter assay and cytotoxicity assay:
A stably transfected gene reporter cell line AZ-AHR and AZ-GR established in our laboratory were used for assessment of AhR and GR transcriptional activity. Transiently transfected LS180 human colon adenocarcinoma cells were used for assessment of PXR transcriptional activity. A chimera p3A4-luc reporter construct containing the basal promoter (-362/+53) with proximal PXR response element and the distal xenobiotic responsive enhancer module (-7836/-7208) of the CYP3A4 gene 50-flanking region inserted to pGL3-Basic reporter vector was used. The reporter plasmid was transiently transfected to LS180 cells by lipofection (FuGENE® HD Transfection Reagent). Prior to gene reporter assays, we examined the cytotoxicity of tested compounds in AZ-AHR, AZ-GR and LS180 cell lines. For this purpose, the cells were incubated for 24 h with individual enantiomers of atorvastatin, fluvastatin and rosuvastatin at concentrations ranging from 100 pM to 100 μM. The vehicle was DMSO (0.1% v/v). After the treatment, a conventional MTT test was performed and absorbance was measured at 540 nm (Figure 2 ). The data are the mean ± SD from experiments performed in three consecutive passages of cells and are expressed as percentage of viability of control cells. The values of IC50 were calculated where appropriate and they are indicated in plots. Based on the results from cytotoxicity testing (Figure 2 ), gene reporter assays were performed in concentrations of tested compounds up to 100 μM, with exception of atorvastatin, where maximal concentration of 10 μM was used for incubations in AZ-AHR and AZ-GR cells. Transcriptional activity of GR was assessed in human gene reporter cell line AZ-GR incubated for 24 h with tested compounds. Dexamethasone (100 nM) was used as a model agonist. None of the tested statins induced GR-dependent luciferase activity. Dexamethasone-inducible transcriptional activity of GR was decreased by antagonized by 3R5R-atorvastatin (10 mM) and 3R5S-rosuvastatin (100 mM), but the decrease occurred probably due to the cytotoxicity of tested compounds. 3S5S-, 3R5R-and 3R5S-fluvastatin dose-dependently antagonized GR and there were significant differences between fluvastatin optical isomers ( Figure 4) . Transcriptional activity of PXR was tested in human colon adenocarcinoma cells LS180 transiently transfected with p3A4-luc reporter construct, incubated for 24 h with tested compounds. Rifampicin (10 μM) was used as a model agonist. Transcriptional activity of PXR was dose-dependently induced by all tested statins, and the potency and efficacy between individual optical isomers varied substantially. Rifampicin-inducible transcriptional activity of PXR was influenced by all tested statins, again differentially, depending on statin and optical isomer ( Figure 5) . 
Conclusion

